Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Merck
Moodys
McKesson
Mallinckrodt

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Interferon beta-1a - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for interferon beta-1a

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Allergy- and pulmonary Clinic, Vanloese.Phase 4
Bispebjerg HospitalPhase 4
Lund UniversityPhase 4

See all interferon beta-1a clinical trials

Recent Litigation for interferon beta-1a

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Amgen Inc. v. Accord Healthcare, Inc.2018-06-28
Idenix Pharmaceuticals LLC v. Gilead Sciences, Inc.2014-07-01

See all interferon beta-1a litigation

Pharmacology for interferon beta-1a

Patent Text Search: US Patents for interferon beta-1a

These patents were identified by searching patent claims

International Patents for interferon beta-1a

Supplementary Protection Certificates for interferon beta-1a

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2016 Austria   Start Trial PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, INSVBESONDERE DARUNAVIR-ETHANOLAT; REGISTRATION NO/DATE: EU/1/14/967 (MITTEILUNG) 20141121
2014000079 Germany   Start Trial PRODUCT NAME: SOFOSBUVIR UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON; REGISTRATION NO/DATE: EU/1/13/894 20140116
17002 Norway   Start Trial PRODUCT NAME: KOBICISTAT ELLER FARMASOEYTISK; REG. NO/DATE: EU/1/15/1025 20150810
C0019 Belgium   Start Trial PRODUCT NAME: BETAFERON INTERFERON BETA-1B; REGISTRATION NO/DATE: EU/1/95/003/001 19951130
353 Luxembourg   Start Trial PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE D'ATAZANAVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1025
10/1996 Austria   Start Trial PRODUCT NAME: BETAFERON - INTERFERON BETA-1B
01530064 Spain   Start Trial PRODUCT NAME: COBICISTAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/13/830; DATE OF AUTHORISATION: 20130524; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/830; DATE OF FIRST AUTHORISATION IN EEA: 20130524
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Merck
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.